Product Code: 24-014
"In Vitro Diagnostics Business Outlook" is a bimonthly publication with six issues annually.
SAMPLE VIEW
"In Vitro Diagnostics Business Outlook" offers information and data that you cannot get anywhere else, including:
- Market data and forecasts (growth rates, market size, market share, etc.) to identify growth opportunities
- A comprehensive view of the IVD market with test categories covered and company briefs
- M&A activities, selected partnerships & collaborations, partnership deals, and more
- Industry & region watch to help tailor strategies
- Analysis of news and events and reporting on news not easily available
Table of Contents
Volume 3, Issue 1 – Focus on Molecular HLA Testing
Market Analysis: Molecular HLA/Transplant Testing
- Overview of Molecular HLA/Transplant Testing
- Market Outlook
- Regional Market
- Top Company Briefs
- Immucor
- Luminex/DiaSorin
- CareDx
- Thermo Fisher Scientific
- Executive News Briefing
- DEKFI Diagnostics Appoint New CEO
- Onera Raises $32 Million in Funding
- Cleveland Diagnostics Completes $75 Million in Funding
- Financial Highlights: Agilent and Hologic
- Agilent Full Year Fiscal 2023 Sales up 1.5% in Core Business YOY
- Figure: Agilent Sales, by Business (Agilent CrossLab Group, Diagnostics and Genomics Group, Life Sciences and Applied Markets Group), FY 2022 and FY 2023
- Figure: Agilent Sales, by Business (Agilent CrossLab Group, Diagnostics and Genomics Group, Life Sciences and Applied Markets Group), FY 2023 Quarterly Performance
- Table: Agilent Revenue Mix, by Type (Consumables/Services/Informatics and Instruments), FY 2023 (%)
- Figure: Agilent FY 2023 Regional Sales Breakdown Distribution, by Region (Americas, Asia Pacific, Europe) (%)
- Hologic Supports Strong Financial Performance in Full-Year Fiscal Year Guidance
- Table: Hologic Diagnostic Sales Performance, by Product Group (Blood Screening, Cytology & Perinatal, Molecular Diagnostics), FY 2023 ($ millions)
- Figure: Hologic Revenue, by Product Group (Blood Screening, Cytology & Perinatal, Molecular Diagnostics), FY 2022 and FY 2023 ($ millions)
- Figure: Hologic Geographic Revenue Distribution, by Region (Asia Pacific, Europe, United States, All Others), FY 2023 (%)
- Diagnostic Market Mergers, Acquisitions and Partnership Deals
- Mergers and Acquisitions
- Table: Selected Diagnostic Market Mergers and Acquisitions Deals
Partnerships and Collaborations
- Industry Watch
- COVID-19 Update
- Region Watch
- India
- Figure: India Real GDP Growth, Inflation Rate (consumer prices), 2017-2024
- Figure: India IVD Market Distribution of Sales, by Broad IVD Segment (Chemistry/Hematology/Coagulation, Histology/Cytology, Immunoassays, Microbiology/Virology, Point-of-Care Glucose, Other Segments), 2023 (%)
- Saudi Arabia
- Figure: Saudi Arabia Population Pyramid, 2023 and 2053
- Figure: Saudi Arabia Total Annual Liquid Fuels Production and Consumption, 2013-2022 (millions of barrels)
- Figure: Saudi Arabia IVD Market Share, by Broad IVD Segment (Chemistry/Hematology/Coagulation, Histology/Cytology, Immunoassays, Microbiology/Virology, Point-of-Care Glucose, Other Segments), 2023
- Broad-based Company Announcements
- QuidelOrtho Obtains FDA Nod
- Illumina Plans to Divest Grail
- Roche to Acquire LumiraDx
- QIAGEN Expands Footprint with New Regional Headquarters in Middle East
Volume 3, Issue 2 – Focus on Immunoassay Overview
- Market Analysis
- Overview of IVD Immunoassay
- Market Outlook
- Table: Global Lab-Based Immunoassay Market by Segment, 2023-2028 ($ millions)
- Figure: Global Lab-Based Immunoassay Market, by Segment, 2023-2028 ($ millions)
- Regional Market
- Table: Global Immunoassay Market (Lab-Based) Sales Distribution, by Region, 2023 (%) (North America, Europe, Asia Pacific, Latin America, Middle East, Africa)
- Figure: Global Immunoassay Market Sales Distribution, Top 10 Country Markets, 2023 (%)
- Top Company Briefs
- Roche
- Abbott Diagnostics
- Siemens Healthineers
- Other Selected Immunoassay News
- Executive News Briefing
- NOWDiagnostics Selects New Science Officer
- Freenome Raises $254 Million in New Funding
- QuidelOrtho Axes CEO
- Agilent CEO to Retire
- Financial Highlights: Bio-Rad Laboratories and Veracyte
- Bio-Rad Laboratories Reports Full-Year 2023 Clinical Diagnostics Revenues up 3.2% over previous year
- Table: Bio-Rad Laboratories Net Sales, 2021-2023 ($M)
- Figure: Bio-Rad Laboratories Sales by Business, 2022 vs. 2023, $M
- Figure: Bio-Rad Laboratories Quarterly Performance by Business, 2022 vs. 2023 ($M)
- Figure: Bio-Rad Laboratories 2022 and 2023 Regional Sales Breakdown Distribution
- Veracyte Reported Strong Performance in 2023
- Figure: Veracyte 12-Month (FY22 and FY23) Sales by Division (Testing, Product, Biopharmaceutical and Other), Thousands USD
- Diagnostic Market Mergers, Acquisitions and Partnership Deals
- Mergers and Acquisitions
- Table: Selected Diagnostic Market Mergers and Acquisitions Deals
- Partnerships and Collaborations
- Industry Watch
- Virus Testing Update
- Region Watch
- Peru
- Figure: Peru Population Distribution by Broad Age Group, 2023 and 2040 Estimates
- Figure: Peru GDP Value and Growth by Year, 2010-2022
- Figure: Peru COVID-19 Lab Samples Tested and Positivity by Region, Cumulative 2020-2023
- South Africa
- Figure: South Africa Population Pyramid, 2023 and 2033 Estimates
- Figure: South Africa GDP, Composition by Sector (Agriculture, Industry, Services)
- Broad-based Company Announcements
- Werfen Receives CE Mark for Aptiva Antiphospholipid Syndrome
- DiaSorin Nabs FDA Clearance for New LIAISON PLEX System
- T2 Biosystems Offers Expanded Panel
- Cepheid Received FDA Clearance for Xpert Xpress GBS
- DiaCarta Collaboration to Launch Prostate Cancer LDT
Volume 3, Issue 3 – Clinical Chemistry
- Market Analysis: Clinical Chemistry
- Overview of Clinical Chemistry Market
- Market Outlook
- Table: Clinical Chemistry Diagnostic Sales, by Broad Test Category, 2023 ($ millions)
- Figure: Clinical Chemistry Diagnostic Market Distribution, by Broad Test Category, 2023 (%)
- Major Product Activity
- Lab-based Clinical Chemistry
- Table: Market Summary: Lab-based Clinical Chemistry Market, by Segment, 2023 and 2028 ($ millions)
- Point-of-Care Clinical Chemistry
- Table: Market Summary: POC-based Clinical Chemistry Market, 2023 and 2028 ($ millions)
- Regional Market
- Figure: Global Clinical Chemistry Sales Estimates and Projection, by Region, 2023 and 2028 ($ millions)
- Table: Global Clinical Chemistry Sales Distribution, by Region, 2023 (%)
- Top Company Briefs
- Executive News Briefing
- Cue Health Calls It Quits
- Allenz Health Secures $60 Million in Funding
- Next Gen Diagnostics Welcomes New Scientific Advisory Board Member
- Next Gen Diagnostics Opens First U.S. Laboratory
- Financial Highlights: bioMérieux & Sekisui Diagnostics
- Figure: bioMérieux Sales Distribution, by Business Segment, 2023 (%)
- Table: bioMérieux Financial Review, by Business Segment, FY 2022 – FY 2-23 (€M)
- Figure: bioMérieux FY 2022 vs FY 2023 Regional Sales Breakdown (€M)
- Table: Sekisui Chemical Financial Results, FY 2022 and FY 2023 (Billions of Yen)
- Table: Sekisui Chemical Annual Overview and Focus, FY 2023 and FY 2024 (Billions of Yen)
- Table: Sekisui Chemical Net Sales, by Segment, FY22 and FY23 (Billions of Yen)
- Figure: Sekisui Chemical Medical Division, Revenue Mix, by Type, by Quarter, Q1 FY22 – Q4FY23 (Millions of Yen)
- Diagnostic Market Mergers, Acquisitions and Partnership Deals
- Mergers and Acquisitions
- Table: Selected Diagnostic Market Mergers and Acquisitions Deals
- Partnerships and Collaborations
- Industry Watch
- COVID-19/Flu Update
- Region Watch
- Japan
- Figure: Japan National Health Expenditures, Year-on-Year Growth Rate, 1985-2019 (Yen trillion, %)
- Figure: Japan: Changes in Number of Hospitals, by Hospital Type, 2015-2019
- Figure: Japan: Changes in Number of Beds, by Bed Type and Number of Beds per Hospital, 2015-2019
- Figure: Japan: Changes in Average Length of Stay, by Bed Type, 2015-2019
- Figure: Japan IVD Market, by Segment, 2023 (%)
- Broad-based Company Announcements
- Announcements
- QIAGEN Launches Gastrointestinal Molecular Panel in the United States
- Illumina Spins Off Grail
- QIAGEN Discontinues NeuMoDx System
- DiaSorin Nabs Clearance for LIAISON PLEX Blood Culture Yeast Assay
- Genetic Signatures Granted FDA Clearance for GI Kit
Volume 3, Issue 4 – Blood Screening
- OVERVIEW OF BLOOD SCREENING
- MARKET OUTLOOK
- Figure: Blood Screening Market, 2019-2029 ($ billion)
- Figure: Blood Screening Sales, by Test Method, 2024 and 2029 ($ billion) (Immunoassay Screen, NAT Screens)
- Figure: Blood Donation Screening Market Distribution, by Analyte, 2024 (%) (Hepatitis, HIV, Other)
- REGIONAL MARKET
- Table: Estimated Blood Donations, by WHO Region, 2018
- Figure: Whole Blood Donations per 1000 Population, 2018
- Table: Blood Screening Market Distribution, by Global Region, 2024 (%) (Asia Pacific, Europe, North America, RoW)
- Figure: Blood Screening Market Distribution of Sales, by Global Region (%) (Asia Pacific, Europe, North America, RoW)
- Segment Activity by Region
- Immunoassays
- Figure: Market Summary: Immunoassay Blood Screening Market, Distribution of Sales, by Region, 2024 (%) (Asia Pacific, Europe, North America, RoW)
- Molecular
- Figure: Market Summary: NAT Blood Screening Market, Distribution of Sales by Region (North America, Europe, Asia Pacific, RoW), 2024
- TOP COMPANY BRIEFS
- Roche
- Grifols
- Abbott
- EXECUTIVE NEWS BRIEFING
- BRIEFS
- Trinity Biotech Engages New CCO
- BillionToOne Closes Financing Deal
- OraSure Technologies Elects New Board Member
- Viome Life Sciences Secures $25 Million in Financing
- Syantra Raises $3.6 Million in A-1 Round Financing
- FINANCIAL HIGHLIGHTS: DEXCOM AND EXACT SCIENCES
- Dexcom Revenues Increase 15% (+$133 million) in Q2 2024
- Figure: Dexcom Revenue Mix, by Product Segment, Q2 2023 and Q2 2024
- Figure: Dexcom Revenue Mix by Product Segment, By Quarter 2022 – Q2 2024
- Table: Dexcom Geographic Revenues, by Region, Q2 2023 and Q2 2024 ($ million)
- Exact Sciences Reports it : Tested a Record Number of Cancer Patients with Oncotype DX
- Figure: Exact Sciences Revenue Mix, by Product Segment, Q2 2023 vs Q2 2024 ($ million)
- Figure: Exact Sciences Revenue Mix, by Product Segment, by Quarter 2022-Q2 2024 ($ million)
- DIAGNOSTIC MARKET MERGERS, ACQUISITIONS AND PARTNERSHIP DEALS
- PARTNERSHIPS AND COLLABORATIONS
- MERGERS AND ACQUISITIONS
- Table: Selected Diagnostic Market Mergers and Acquisitions Deals
- REGION WATCH
- Figure: South Korea GDP, GDP (PPP), and Health Spending, CAGR 2005-2010, 2010-2015, 2015-2020 and 2020-2023 (%)
- Figure: South Korea Medical Tourism Visits Reported, 2009-2023 (# of patients)
- Figure: South Korea Old-Age Dependency Ratio and Aging Index, 1980-2065
- BROAD-BASED COMPANY ANNOUNCEMENTS
- ANNOUNCEMENTS
- Foundation Medicine Gets the Nod for Its Companion Diagnostics
- QuidelOrtho Proud to Announce Clearance for VITROS Syphilis Assay
- AliveDx Receives IVDR-CE Mark for Multiplexed Assay
- T2 Biosystems Scores FDA Pediatric Clearance
- ID-FISH Technology Announces FDA Nod for its Lyme ImmunoBlot
Volume 3, Issue 5 – Point-of-Care (POC)
- Market Analysis: IVD POC Testing
- Overview of IVD POC Testing
- Market Outlook
- Table: Global POC Diagnostic Market, by Broad Segment, 2024 and 2029 ($ million) (professional testing, self-testing)
- Figure: Point-of-Care Diagnostics (COVID-19 vs. non-COVID testing), 2020-2024 ($ million)
- Figure: Global POC Diagnostic Market Distribution, by Segment, 2024 (%) (Cardiac Care; Coagulation; Critical Care; Drug of Abuse; Fecal Occult Blood; Glucose; Hematology; Infectious Disease Lipid [Cholesterol]; Pregnancy/Fertility; Urinalysis; Others)
- Selected Product Activity
- Regional Market
- Figure: POC Diagnostics Market Value, by Global Region, 2024 ($ million) (North America, Europe, Asia Pacific, Latin America, Middle East, Africa)
- Company Briefs
- Abbott Diagnostics
- Dexcom
- Roche
- Executive News Briefing
- Briefs
- Quanterix Appoints New Member to Board of Directors
- Beckman Coulter Appoints New President
- MARAbio Raises $19 Million in Series A Funding
- Amprion Makes Advances in Series B Financing
- Sunbird Bio Closes $14 Million Financing Round
- Bruker Reported 17% Growth in Second Quarter 2024 and 11% Growth for the First Six Months
- Figure: Bruker Corporation Sales, by Business, H1 2023 Compared to H1 2024 (Bruker BioSpin, Bruker CALID, Bruker Nano, BEST, Eliminations)
- Figure: Bruker CALID Quarterly Performance, Sales by Quarter, Q1 2022 – Q2 2024
- Figure: Bruker Corporation H1 2023 and H1 2024 Regional Sales Breakdown Distribution (Asia Pacific, Japan; Europe; United States; Other)
- Myriad Genetics Reports 13% Revenue Growth in First Half 2024
- Table: Myriad Genetics Revenue Mix, by Product, H1 2023 vs H1 2024 ($ million) (Hereditary Cancer; Pharmacogenomics; Prenatal; Tumor Profiling)
- Figure: Myriad Genetics Revenue Mix, by Business Unit, Quarterly Performance Q1 2023 through Q2 2024 ($ million) (Mental Health, Oncology, Womens Health)
- Diagnostic Market Mergers, Acquisitions and Partnership Deals
- Partnerships and Collaborations
- Mergers and Acquisitions
- Table: Recent Diagnostic Market Mergers, Acquisitions and Partnership Deals
- Industry Watch
- Industry Watch COVID-19/Flu Update
- Region Watch
- Finland
- Figure: Finland GDP Value and Growth, by Year, 2013-2023 ($ billion)
- Figure: Finland Social Protection Expenditure by Function, 1995-2022 in 2022 Prices (€ billion)
- Figure: Finland IVD Market, 2019-2024 ($ million)
- Broad-based Company Announcements
- Announcements
- Roche Launches TAGS Technology Test
- Exact Sciences Welcomes New Cologuard Plus Test
- PreAnalytiX Launches PAXgene Urine Liquid Biopsy Set
- Abionic Launches Early Sepsis Test
- QIAGEN Expands Liquid Biopsy Portfolio
- FoundationOne Gains Liquid CDx Approval
- Revvitys Euroimmun Announces Groundbreaking Launch in the EU
Volume 3, Issue 6 – Glucose Testing
MARKET ANALYSIS: IVD GLUCOSE TESTING
OVERVIEW OF IVD GLUCOSE TESTING
- MARKET OUTLOOK
- Table: Global Diabetes Sales, by Test Category, 2024-2029 ($ million) (Glucose OTC; Glucose Professional; Glucose, Continuous; HbA1c POC; HbA1c Lab)
- Figure: Global Diabetes Testing Market, by Segment with CAGR 2024-2029 ($ million) (Glucose OTC; Glucose Professional; Glucose, Continuous; HbA1c POC; HbA1c Lab)
- REGIONAL MARKET
- Figure: Global Diabetes Prevalence, 20-79y, 2021 Estimates (per 1,000s)
- Figure: Global Distribution, Diabetes Test Market, 2024 (%) (Glucose, HbA1c)
- COMPANY BRIEFS
- Abbott Diagnostics
- Dexcom
- Roche
EXECUTIVE NEWS BRIEFING
- BRIEFS
- Agilent Reorganizes Business Units
- Natera Co-Founder Named R&D Leader of the Year
- QIAGEN Moves QIAstat-Dx to Drive Growth
- OraSure Receives Funding
- AmplifiDx Captures Additional Funding
- 52North Closes $6 Million in Funding
FINANCIAL HIGHLIGHTS: ABBOTT LABORATORIES, QIAGEN
- ABBOTT CONTINUES STEADY PERFORMANCE IN 2024; 9M SALES INCREASE 3.7%
- Figure: Abbott Sales by Business, 9M 2023 and 9M 2024 ($ million)
- Table: Diagnostic Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
- Figure: Diagnostic Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
- Table: COVID-19 Test Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
- Figure: Diabetes Care, Abbott Laboratories, 9M 2023 and 9M 2024 ($ million)
- QIAGEN REPORTS STRONG PERFORMANCE IN Q3 2024; RAISES GUIDANCE
- Figure: QIAGEN Revenue Mix by Business Segment, 9M 2024 ($ million) (Molecular Diagnostics, Life Sciences)
- Figure: QIAGEN Sales by Product Group, 9M 2024 ($ million) (Sample Technologies, Diagnostic Solutions, PCR/Nucleic Acid Amplification, Genomics/NGS, Other)
- Table: QIAGEN Sales, by Product Type, 9M 2023 and 9M 2024 ($ million) (CAGR %) (Consumables and Related Revenues, Instruments)
- Figure: QIAGEN Diagnostic Solutions Sales, by Segment, 9M 2023 and 9M 2024 ($ million) (QuantiFERON, QIAstat-Dx, NeuMoDx, Other)
- Figure: QIAGEN Sales, by Geographic Region, 9M 2023 and 9M 2024 ($ million) (Americas, EMEA, Asia Pacific/Japan)
DIAGNOSTIC MARKET MERGERS, ACQUISITIONS AND PARTNERSHIP DEALS
- PARTNERSHIPS AND COLLABORATIONS
- MERGERS AND ACQUISITIONS
- Table: Recent Diagnostic Market Mergers, Acquisitions and Partnership Deals, Dec. 2023-Nov. 2024
INDUSTRY WATCH
- INDUSTRY WATCH COVID-19/FLU UPDATE
REGION WATCH
- VIETNAM
- Figure: Vietnam GDP, Composition by Sector, 2023 (%) (Agriculture, Forestry, Fishery; Industry, Construction; Services)
- Figure: Vietnam GDP Value and Growth by Year, 2015-2023 ($ billion)
BROAD-BASED COMPANY ANNOUNCEMENTS
- ANNOUNCEMENTS
- Roche Receives FDA Expanded Approval
- Foundation Medicine Received FDA Companion Diagnostic Approval
- Deepull Receives FDA Breakthrough Device Designation
- bioMérieux Snags Clearance for Tropical Fever Panel
- Roche Receives CE Mark for New Cobas Systems 2.0
- Agilent Received Certification for Companion Diagnostic